Wells Fargo
THRX

Wells Fargo’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Wells Fargo’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,211
Closed -$25.2K – 7800
2023
Q4 		$25.2K Buy
6,211
+1,230
+25% +$3.75K ﹤0.01% 5548
2023
Q3 		$13.4K Sell
4,981
-2,728
-35% -$10.7K ﹤0.01% 5729
2023
Q2 		$71.9K Buy
7,709
+4,702
+156% +$46.3K ﹤0.01% 5227
2023
Q1 		$26.7K Buy
+3,007
New +$29.5K ﹤0.01% 5516
2022
Q4 		– Sell
-32
Closed – – 7818
2022
Q3 		$0 Sell
32
-141
-82% -$996 ﹤0.01% 7651
2022
Q2 		$1K Sell
173
-2,326
-93% -$19.2K ﹤0.01% 6667
2022
Q1 		$29K Sell
2,499
-4,275
-63% -$45.7K ﹤0.01% 5883
2021
Q4 		$86K Buy
+6,774
New +$102K ﹤0.01% 5719

Wells Fargo's THRX Position: Q1 2024 in Review

Wells Fargo sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 6,211 shares — an estimated $25.2K sold.

Wells Fargo first reported a position in THRX in Q4 2021 and held it in 8 quarters. The position peaked at $86K in Q4 2021. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Wells Fargo reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Wells Fargo sold 6,211 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $25.2K.
  • Wells Fargo first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Wells Fargo's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $86K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.